Industry

– Financing Round Led by OrbiMed with participation from Lumira Ventures, Harrington Discovery Institute and existing investors Advent Life Sciences and Belinda Termeer – Therapy development focused on addressing a fundamental mechanism in cancer-driving oncogenes NATICK, Mass.–(BUSINESS WIRE)–PIC Therapeutics, Inc., a biopharmaceutical company dedicated to developing life-changing medicines for patients with cancer, today announced the … [Read more…]

Funding increases company’s investment in New Mexico to over $380,000, enabling local organizations to address social determinants of health ALBUQUERQUE, N.M.–(BUSINESS WIRE)–As part of an ongoing effort to address vital social determinants of health across New Mexico, UnitedHealthcare has awarded three New Mexico-based organizations $188,000 in community grants to address behavioral and maternal health in … [Read more…]

Conducted by Vitro Biopharma, the trial aims to investigate the safety and efficacy of intravenous infusions of its stem cell therapy product SANTA ANA, Calif.–(BUSINESS WIRE)–FUJIFILM Irvine Scientific, Inc., a world leader in the development and manufacture of serum-free and chemically defined cell culture media for bioproduction and cell therapy manufacturing, today announced that its … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Oncolytic Virus Therapy Market Research and Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. Oncolytic virus therapy is based on the treatment through a virus that infects and kills cancer cells. The global oncolytic virus therapy market is anticipated to grow at a considerable CAGR of over 15% during the forecast … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Indian Pharmaceutical Contract Manufacturing Market Research and Forecast 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The Indian pharmaceutical contract manufacturing market is anticipated to grow at a favourable CAGR of around 13.3% during the forecast period. Being one of the free trade agreement members, India holds the access to the best established … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Tempo Bioscience, Inc. (“Tempo”) a privately-held biotechnology company based in San Francisco, California, has released new human induced pluripotent stem cell (iPSC) derived cell products and affiliated cell-based services in the following categories: Tempo-iBMEC™   Human iPSC-derived Brain Microvascular Endothelial Cells Tempo-iPeri™   Human iPSC-derived Pericytes Tempo-iBMEC™ and Tempo-iPeri™ are critical for establishing … [Read more…]

Leader in Care for Medicare-Eligible Beneficiaries to Begin Enrolling Members in Alabama, Colorado, Hawaii, North Carolina, Oregon, Pennsylvania, South Carolina, and Tennessee WALTHAM, Mass.–(BUSINESS WIRE)–Devoted Health, an all-in-one healthcare company delivering complete, coordinated, and customized care for Medicare-eligible beneficiaries, announced today that it has launched Devoted Medicare Advantage plans and Devoted Medical services across eight … [Read more…]

LAVAL, Canada–(BUSINESS WIRE)–Altasciences’ laboratory facilities in Columbia, MO, are undergoing a significant expansion, with completion expected in 2023. The new 8,000-square-foot space will mirror Altasciences’ current bioanalytical laboratory in Laval, Québec, with state-of-the-art equipment and bioanalytical capabilities. This will supplement the service offering already available at Altasciences’ site in Seattle, WA, to support preclinical and … [Read more…]

HOUSTON–(BUSINESS WIRE)–#hepatocellularcarcinoma–Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced that its lead product, TTI-101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory locally advanced, unresectable, or metastatic hepatocellular carcinoma (HCC). The FDA has … [Read more…]

Will provide companies in late pre-clinical to early-clinical stages of development access to high-quality trial sites in Arkansas to bring groundbreaking therapies to market faster Designed to increase Arkansans’ access to cutting-edge clinical care and innovative medicines Application now open for inaugural cohort beginning in April 2023 BENTONVILLE, Ark.–(BUSINESS WIRE)–SymBiosis Capital Management, LLC (“SymBiosis”) and … [Read more…]